We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement

TriLink Enters into Distribution Agreement with TATAA Biocenter

Listen with
Speechify
0:00
Register for free to listen to this article
Thank you. Listen to this article using the player above.

Want to listen to this article for FREE?

Complete the form below to unlock access to ALL audio articles.

Read time: Less than a minute
Scandinavian based TATAA develops and performs a broad spectrum of hands-on qPCR courses worldwide, in addition to providing tailor-made products for real-time PCR applications.

As an innovative approach to Hot Start PCR, TriLink’s CleanAmp™ Product Line is an ideal complement to TATAA’s product and service offerings. In developing CleanAmp™, TriLink applied its expertise in modified nucleic acid chemistry to resolve common PCR problems, such as primer dimer formation and mis-priming. This advancement in Hot Start technology employs two widely ignored components of the PCR reagent mix: the primers and the dNTPs. The latest addition to the CleanAmp™ Product Line will be new, improved CleanAmp™ dNTPs, which will be available in April 2011. The latest advancement in CleanAmp™ dNTP chemistry allows improved amplicon yield in endpoint PCR and earlier Cq values in fast cycling real-time PCR.

“TATAA has established itself as a thought leader in the field of real-time PCR, and we are excited about the opportunity to expose our CleanAmp™ technology to the international research community through its training courses. We are confident that TATAA and its clients will be pleased with the results they see using CleanAmp™ Products,” stated TriLink’s President and CEO, Richard Hogrefe.

“The CleanAmp™ hot-start technique developed at TriLink is so much more versatile and easy to implement compared to alternatives, and being supported by our application specialists, we expect it will become a most popular product,” says Mikael Kubista, founder and CEO of TATAA Biocenter.